|
[1]
|
Park H, Bourla AB, Kastner DL, et al.Lighting the fires within:the cell biology of autoinflammatory diseases[J]. Nat Rev Immunol, 2012, 12:570-580. doi: 10.1038/nri3261 |
|
[2]
|
Vastert SJ, Kuis W, Grom AA. Systemic JIA:New developments in theunderstanding of the pathophysiology and therapy[J]. Best Pract Res Clin Rheumatol, 2009, 23:655-664. doi: 10.1016/j.berh.2009.08.003 |
|
[3]
|
Yokota S, Kikuchi M, Nozawa T, et al. Pathogenesis of systemic inflammatory diseases in childhood:"Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome"[J].Mod Rheumatol, 2015, 25:1-10. doi: 10.3109/14397595.2014.902747 |
|
[4]
|
Mellins ED, Macaubas C, Grom AA, et al. Pathogenesis of systemic juvenile idiopathic arthritis:some answers, more questions[J].Nat Rev Rheumatol, 2011, 7:416-426. doi: 10.1038/nrrheum.2011.68 |
|
[5]
|
Barker BR, Taxman DJ, Ting JP. Cross-regulation between the IL-1beta/IL-18 processing inflammasome and other inflammatory cytokines[J]. Curr Opin Immunol, 2011, 23:591-597. doi: 10.1016/j.coi.2011.07.005 |
|
[6]
|
Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation:putative role in pathogenesis and usefulness as biomarkers[J]. Clin Immunol, 2013, 147:229-241. doi: 10.1016/j.clim.2012.11.008 |
|
[7]
|
Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis:some answers, more questions[J]. Nat Rev Rheumatol, 2011, 7:416-426. doi: 10.1038/nrrheum.2011.68 |
|
[8]
|
Llamas-Covarrubias MA, Valle Y, Bucala R, et al.Macrophage migration inhibitory factor (MIF):genetic evidence for participation in early onset and early stage rheumatoid arthritis[J].Cytokine, 2013, 61:759-765. doi: 10.1016/j.cyto.2012.12.032 |
|
[9]
|
Wakil SM, Monies DM, Abouelhoda M, et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis[J]. Arthritis Rheumatol, 2015, 67:288-295. doi: 10.1002/art.38877 |
|
[10]
|
de Jesus AA, Goldbach-Mansky R. Newly recognized Mendelian disorders with rheumatic manifestations[J]. Curr Opin Rheumatol, 2015, 27:511-519. doi: 10.1097/BOR.0000000000000207 |
|
[11]
|
Balow JE Jr, Ryan JG, Chae JJ, et al. Microarray-based gene expressionprofiling in patients with cryopyrin-associated periodic syndromes defines adisease-related signature and IL-1-responsive transcripts[J]. Ann Rheum Dis, 2013, 72:1064-1070. doi: 10.1136/annrheumdis-2012-202082 |
|
[12]
|
Ayaz NA, Ozen S, Bilginer Y, et al. MEFV mutations in systemic onset juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2009, 48:23-25. http://www.ncbi.nlm.nih.gov/pubmed/18984609 |
|
[13]
|
Hinks A, Martin P, Thompson SD, et al. Autoinflammatory gene polymorphisms and susceptibility to UK juvenile idiopathic arthritis[J].Pediatr Rheumatol Online J, 2013, 11:14. doi: 10.1186/1546-0096-11-14 |
|
[14]
|
Sikora KA, Grom AA. Update on the pathogenesis and treatment of systemic idiopathic arthritis[J]. Curr Opin Pediatr, 2011, 23:640-646. doi: 10.1097/MOP.0b013e32834cba24 |
|
[15]
|
Gaspari S, Marcovecchio ML, Breda L, et al. Growth in juvenile idiopathic arthritis:the role of inflammation[J].Clin Exp Rheumatol, 2011, 29:104-110. http://europepmc.org/abstract/MED/21269577 |
|
[16]
|
Yokota S, Imagawa T, Mori M, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan[J].J Rheumatol, 2014, 41:759-767. doi: 10.3899/jrheum.130690 |
|
[17]
|
Kostik MM, Dubko MF, Masalova VV, et al. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis[J].Pediatr Rheumatol Online J, 2015, 23:13-17. doi: 10.1186/1546-0096-13-4 |
|
[18]
|
Izumi K, Kaneko Y, Yasuoka H, et al. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors:a single-center retrospective cohort study (KEIO-TCZ study) at week 52[J]. Mod Rheumatol, 2015, 25:31-37. doi: 10.3109/14397595.2014.897793 |
|
[19]
|
De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis[J]. N Engl J Med, 2012, 367:2385-2395. doi: 10.1056/NEJMoa1112802 |
|
[20]
|
Ilowite NT, Prather K, Lokhnygina Y, et al.Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis[J].Arthritis Rheumatol, 2014, 66:2570-2579. doi: 10.1002/art.38699 |
|
[21]
|
Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France:a nationwide survey[J].Orphanet J Rare Dis, 2015, 15:10-19. http://pubmedcentralcanada.ca/pmcc/articles/PMC4340831/ |
|
[22]
|
Frosch M, Ahlmann M, Vogl T, et al. Themyeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor4, and interleukin-1beta form a positive feedback mechanism in systemic-onsetjuvenile idiopathic arthritis[J]. Arthritis Rheum, 2009, 60:883-891. doi: 10.1002/art.24349 |
|
[23]
|
Wilson DC1, Marinov AD, Blair HC, et al. Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis[J]. Arthritis Rheum, 2010, 62:2510-2516. doi: 10.1002/art.27485 |
|
[24]
|
deJager W, Hoppenreijs EP, Wulffraat NM, et al. Blood and synovial fluid cytokine signatures in patients withjuvenile idiopathic arthritis:a cross-sectional study[J]. Ann Rheum Dis, 2007, 66:589-598. doi: 10.1136/ard.2006.061853 |
|
[25]
|
Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemicjuvenile idiopathic arthritis based on their cytokine profiles[J]. Cytokine, 2013, 61:345-348. doi: 10.1016/j.cyto.2012.11.025 |
|
[26]
|
Ravelli A, Minoia F, Davì S, et al.Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis[S/OL].Arthritis Rheumatol, 2015, 8.http://www.researchgate.net/publication/281325601. doi: 10.1002/art.39332. |
|
[27]
|
Reddy VV, Myles A, Cheekatla SS, et al. Soluble CD25 in serum:a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis[J].Int J Rheum Dis, 2014, 17:261-267. doi: 10.1111/1756-185X.12196 |
|
[28]
|
Ibarra MF, Klein-Gitelman M, Morgan E, et al. Serum neopterin levels as a diagnostic marker of hemophagocyticlymphohistiocytosis syndrome[J]. Clin Vaccine Immunol, 2011, 18:609-614. doi: 10.1128/CVI.00306-10 |
|
[29]
|
Hazen MM, Woodward AL, Hofmann I, et al. Mutations of thehemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis[J]. Arthritis Rheum, 2008, 58:56-570. |
|
[30]
|
Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndromein patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms[J]. Arthritis Rheum, 2008, 58:2892-2896. doi: 10.1002/art.23734 |
|
[31]
|
Yanagimachi M, Goto H, Miyamae T, et al. Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children[J].J Clin Immunol, 2011, 31:946-951. doi: 10.1007/s10875-011-9583-x |
|
[32]
|
Yanagimachi M, Naruto T, Miyamae T, et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis[J].J Rheumatol, 2011, 38:769-774. doi: 10.3899/jrheum.100655 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
